Nama's AI scorecard currently rates agilon health Sell (3.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does AGL report earnings?

agilon health's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$2.98.

What is the AGL price target?

The median analyst price target from 12 analysts is $115.00, with a range of $85.00 – $146.00.

Is AGL Shariah compliant?

Nama's AAOIFI-style screen reads agilon health as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

agilon health (AGL)

Healthcare · Medical Care Facilities · NYSE

agilon health (AGL) is a Healthcare company in the Medical Care Facilities industry. It has a market capitalization of $1.90B and a free-cash-flow yield of -7.9%. Over the most recent reported fiscal year, revenue declined 2.1%. Nama's AI scorecard rates it Sell, 3.6 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Sell · 3.6/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Leading · +391.7% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-84.6%

How far the last close sits under the highest price of the past five years.

Market cap	$1.90B
Trailing P/E	—
Price / book	8.4
Price / sales	0.3
FCF yield	-7.9%
Dividend yield	—
Gross margin	0.2%
Operating margin	-4.6%
Net margin	-3.9%
Revenue growth (YoY)	-2.1%
Revenue growth (3-yr annual)	+35.4%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	3.0
Exchange	NYSE
Sector	Healthcare
Industry	Medical Care Facilities

AGL earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate -$2.98). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	$1.97	-$1.47	+234.0%	$1.52B
Q2 2026	Aug 5, 2026	$2.15	$0.27	+696.3%	$1.49B
Q1 2026	May 6, 2026	$2.32	$0.93	+149.5%	$1.42B
Q4 2025	Feb 25, 2026	-$8.95	-$6.85	-30.7%	$1.57B

AGL analyst price target

Median target $115.00 from 12 analysts, ranging $85.00 – $146.00.

Medical Care Facilities peers

Ticker	Company	Market cap	P/E
HCA	HCA Healthcare	$103.40B	16.5
THC	Tenet Healthcare	$22.55B	12.7
EHC	Encompass Health	$13.50B	22.4
FMS	Fresenius Medical Care	$12.15B	10.2
DVA	DaVita	$12.04B	13.6
UHS	Universal Health Services	$11.52B	8.6
ENSG	Ensign Group	$10.56B	23.8
PACS	PACS Group	$7.87B	20.1

Explore live AGL data on Nama Insights →

AGL FAQ

Is AGL a buy?: Nama's AI scorecard currently rates agilon health Sell (3.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does AGL report earnings?: agilon health's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$2.98.
What is the AGL price target?: The median analyst price target from 12 analysts is $115.00, with a range of $85.00 – $146.00.
Is AGL Shariah compliant?: Nama's AAOIFI-style screen reads agilon health as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.